Building on this, Futamura et al. (2021) focuses on nanoparticle albumin-bound paclitaxel (nab-PTX) in neoadjuvant settings for operable breast cancer.159 Their meta-analysis demonstrated robust pathological complete response (pCR) rates across various breast cancer subtypes, particularly HER2-rich and TNBC. This evidence concerns the gene ERBB2 and breast cancer.